Did the FDA approve IV and subcutaneous atezolizumab for dMMR colon cancer?

Yes. The article says the FDA cleared both intravenous and subcutaneous atezolizumab for dMMR colon cancer, making this both an indication expansion and a delivery-format event. It notes the subcutaneous option could matter for site-of-care logistics, chair time, and buy-and-bill economics.